{"nctId":"NCT01631825","briefTitle":"A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients","startDateStruct":{"date":"2009-10"},"conditions":["Parkinson's Disease"],"count":321,"armGroups":[{"label":"SPM 962","type":"EXPERIMENTAL","interventionNames":["Drug: SPM 962"]}],"interventions":[{"name":"SPM 962","otherNames":["rotigotine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject completed the preceding trial 243-08-001.\n\nExclusion Criteria:\n\n* Subject discontinued from the preceding trial 243-08-001.\n* Subject had a serious adverse event which association with the investigational drug was not ruled out during trial 243-08-001.\n* Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-08-001.\n* Subject had persistent confusion, hallucination, delusion or excitation during trial 243-08-001.\n* Subject has abnormal behavior such as obsessive-compulsive disorder and delusion in 243-08-001 study.\n* Subject showed serious or extensive application site reactions beyond the application site in the 243-08-001 study.\n* Subject has orthostatic hypotension or a systolic blood pressure (SBP) \\<= 100 mmHg and has a decrease of SBP from spine to standing position \\>= 30 mmHg at baseline.\n* Subject has a history of epilepsy, convulsion etc. during trial 243-08-001.\n* Subject develops serious ECG abnormality at the baseline.\n* Subject has QTc-interval \\>= 500 msec at the baseline or subject has an increase of QTc-interval \\>= 60 msec from the baseline in the trial 243-08-001 and has a QTc-interval \\> 470 msec in female or \\> 450 msec in male at the baseline.\n* Subject had a serum potassium level \\< 3.5 mEq/L at the end of the taper period in trial 243-08-001.\n* Subject has a total bilirubin \\>= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or ? 100 IU/L) at the end of the period in trial 243-08-001.\n* Subject had BUN \\>= 30 mg/dL or serum creatinine \\>= 2.0 mg/dl at the end of the taper period in trial 243-08-001.\n* Subject who plans pregnancy during the trial.\n* Subject is unable to give consent.\n* Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters","description":"The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters.\n\nAEs of special interest (1-3) are defined as below:\n\n1. sudden onset of sleep\n2. obsessive-compulsive disorder or impulse-control disorder\n3. hallucination, delusion\n\nApplication site reaction is scored as -, Â±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"311","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"269","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score","description":"Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state).\n\nUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"UPDRS Part 2 Sum Score (Average of on State and Off State)","description":"Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state).\n\nUPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"3.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"4.0"}]}]}]},{"type":"SECONDARY","title":"Absolute Time Spent \"Off\"","description":"Mean number of hours in \"off state\" during a 24-hour period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"UPDRS Part 1 Sum Score","description":"Mean change (LOCF) from baseline in UPDRS Part 1 sum score.\n\nUPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"1.29"}]}]}]},{"type":"SECONDARY","title":"UPDRS Part 2 Sum Score (On State)","description":"Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"UPDRS Part 2 Sum Score (Off State)","description":"Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"5.5"}]}]}]},{"type":"SECONDARY","title":"UPDRS Part 4 Sum Score","description":"Mean change (LOCF) from baseline in UPDRS Part 4 sum score.\n\nUPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score.\n\nA higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"1.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score","description":"Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score.\n\nA decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.4","spread":"9.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1","spread":"10.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"12.1"}]}]}]},{"type":"SECONDARY","title":"The Modified Hoehn & Yahr Severity of Illness","description":"Change (LOCF) from baseline in the Modified Hoehn \\& Yahr Severity of Illness. The Modified Hoehn \\& Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.\n\nThe data at week 52 is shown.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Each Item of UPDRS Part 1","description":"The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Each Item of UPDRS Part 2 (on State)","description":"The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Each Item of UPDRS Part 2 (Off State)","description":"The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Each Item of UPDRS Part 2 (Average of on State and Off State)","description":"The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Total of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State)","description":"Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state).\n\nA decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"11.4"}]}]}]},{"type":"SECONDARY","title":"Each Item of UPDRS Part 3 (on State)","description":"The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Each Item of UPDRS Part 4","description":"The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":321},"commonTop":["Application Site Reaction","Nasopharyngitis","Dyskinesia","Hallucination Visual","Nausea"]}}}